(C) 2011 Wiley Periodicals, Inc. J Appl Polym Sci 123: 2534-2539, 2012″
“Study Design. Review of historical archival records.
Objective. Describe Harvey Cushing’s patients with spinal pathology.
Summary of Background Data. Harvey Cushing was a pioneer of modern surgery but his work on spine remains largely unknown.
Methods. Review CH5183284 of the Chesney Medical Archives of the Johns Hopkins Hospital
from 1896 to 1912.
Results. This is the first time that Cushing’s spinal cases while he was at the Johns Hopkins Hospital, including those with Pott disease, have been described.
Cushing treated three young men with psoas abscesses secondary to Pott disease during his residency: he drained the abscesses, debrided any accompanying necrotic vertebral bodies, irrigated the cavity with salt, and left the incision open to close by secondary intention. Although Cushing used Koch’s “”tuberculin therapy”" (of intravenous administration of isolated tubercular bacilli) in one patient, he did not do so in the other two, likely because of the poor response of this first patient. Later in his tenure, Cushing performed a laminectomy on a patient with kyphosis and paraplegia secondary to Pott disease.
Conclusion. These cases provide a view of Cushing early in his career, pointing CHIR-99021 to the extraordinary
degree of independence that he had during his residency under William Steward Halsted; these cases may have been important in the surgical upbringing both of Cushing and his coresident, William Stevenson Baer, who became the first professor of Orthopedics at Johns Hopkins Hospital. At the turn of the last century, Pott disease was primarily treated by immobilization with bed rest, braces, and plaster-of-paris jackets; some surgeons also employed gradual correction of the deformity by hyperextension. Patients who failed a
trial of conservative therapy (of months to years) were treated with a laminectomy. However, the limitations of these strategies led to the development of techniques that form the basis of contemporary spine surgery-instrumentation and fusion.”
“Purpose: Recently, it was PI3K cancer found that MK615 possessed an anti-proliferative ability on treated cancer cells as a consequence of triterpenoid compounds. It is well known that radiation affects cellular-mediated immunity in cancer patients who are treated with radiotherapy. Similarly, the ability of triterpenoid compounds to enhance the cellular-mediated immunity has been observed. Therefore, in the present study, we attempted to investigate the effect of MK615 on both cancer cells and cellular-mediated immunity after irradiation.